Vectibix Amgen - Treatment for Metastatic Colorectal Cancer
Vectibix is a recombinant, human IgG2 kappa monoclonal antibody indicated for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on, or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.Posted: September 2006
Related Articles:
- Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab - March 30, 2006
Vectibix (panitumumab) FDA Approval History
